Chronic myelogenous leukemia--identifying the hydra's heads.
Clarke
Michael F
MF
Department of Medicine, University of Michigan Medical School, Ann Arbor, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D001752:Blast Crisis / Q000503:physiopathology; D003598:Cytoskeletal Proteins / Q000378:metabolism*; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism; D006412:Hematopoietic Stem Cells / Q000502:physiology*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000378:metabolism / Q000503:physiopathology* / Q000628:therapy; D039902:Multipotent Stem Cells / Q000502:physiology; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D015534:Trans-Activators / Q000378:metabolism*; D051176:beta Catenin
D000970:Antineoplastic Agents; D001549:Benzamides; C495270:CTNNB1 protein, human; D003598:Cytoskeletal Proteins; D010879:Piperazines; D011743:Pyrimidines; D015534:Trans-Activators; D051176:beta Catenin; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl